New Drug Approvals Archive

Lexapro (escitalopram oxalate) Tablets and Oral Solution

Date of Approval: August 14, 2002
Company: Forest Laboratories, Inc.
Treatment for: Depression, Generalized Anxiety Disorder

Lexapro (escitalopram oxalate) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder and for the treatment of generalized anxiety disorder (GAD).

• Lexapro, The Single-Isomer of Celexa, Receives FDA Approval For the Treatment of Major Depression

Lexapro (escitalopram oxalate)

New Indication Approved: August 29, 2002

• Lexapro Approved as Maintenance Treatment for Major Depressive Disorder

Lexapro (escitalopram oxalate)

New Dosage Form Approved: November 27, 2002

• Lexapro Oral Solution Formulation Provides New Option for Depressed Patients

Lexapro (escitalopram oxalate)

New Indication Approved: December 18, 2002

• Lexapro Receives FDA Approval for the Treatment of Generalized Anxiety Disorder

Eloxatin (oxaliplatin)

New Formulation Approved: January 31, 2005

• Eloxatin Sanofi-Synthelabo - Treatment for Advanced Carcinoma of the Colon or Rectum

Lexapro (escitalopram oxalate)

Patient Population Altered: March 20, 2009

• Forest Laboratories, Inc. Announces FDA Approval of Lexapro for the Treatment of Major Depressive Disorder in Adolescents